Characterization of the genotoxic potential of chemical substances is essential for safety assessment. A battery of complementary tests is generally recommended, including the Ames bacterial mutagenesis test, mouse lymphoma assay (MLA) and chromosomal aberration test. In addition, in vivo genotoxicity assays using rodent models have been used to evaluate genetic damage occurring after metabolic processes in living organisms. The micronucleus test of mouse erythrocytes or bone marrow is regarded as one of the standard methods of testing for in vivo genotoxicity but has limitations regarding tissue specificity. For instance, diethylnitrosamine (DEN), a well-known hepatic mutagen/carcinogen, has been shown to be negative for the micronucleus test in hematopoietic cells. Thus, the development of in vivo evaluation methods to detect organ-specific genotoxicity is a high priority.

Endogenous DNA damage arises from various pathways involving reactive oxygen species, spontaneous hydrolysis and exposure to UV light. Nucleotides affected by sequence errors are usually replaced by repair mechanisms after the removal of a short segment of a damaged strand and copying from the intact complementary strand. Alternatively, broken DNA can be repaired by recombination.

The mechanisms of DNA repair are regulated by specific enzymes for each function, and aberrant expression of repair enzymes can cause persistence of damaged DNA and consequent cancer development. Urinary bladder cancer is the seventh most common cancer in males worldwide, with smoking and occupational exposures considered the major risk factors for development of the transitional cell carcinoma. N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN) exhibits specific mutagenicity and carcinogenicity for the urinary bladder. Although BBN-treated rodent models have been widely used for investigation of different aspects of bladder cancer, the mechanisms underlying its tissue-specificity remain unknown. While several previous studies have investigated the association of BBN-induced bladder carcinogenesis and DNA repair, there are only few published reports focusing on the expression of repair enzymes and phosphorylation of histone proteins. In the present study, to evaluate the potential role of DNA repair in bladder carcinogenesis, we examined the expression pattern of various repair enzymes and phosphorylated histone H2A protein (γ-H2AX) in BBN-treated F344 rats using immunohistochemistry.

BBN was purchased from Tokyo Chemical Industry (Tokyo, Japan). Six-week-old specific pathogen-free male rats (F344/DuCrj; Charles River Laboratories Japan, Yokohama, Japan) were housed in polycarbonate cages with soft chip bedding (Sankyo Labo Service, Tokyo, Japan) in a room with a barrier system controlled for the light/dark cycle (12 hr), ventilation (air exchange rate 18 times per hr), temperature (24 ± 1°C) and relative humidity (55 ± 5%) dur-
ing the study. The cages and chip bedding were exchanged twice a week. Each animal had free access to basal diet (CRF-1; Oriental Yeast, Tokyo, Japan) and tap water with or without BBN.

Animals were administered 0.05% BBN in their drinking water for 4 weeks and then maintained without any further treatment for 33 weeks. They were sacrificed under deep anesthesia at 43 weeks of age and subjected to laparotomy with excision of the urinary bladder. Untreated rats at 11 weeks of age were also sacrificed as a control group. The experimental design was approved by the Animal Care and Utilization Committee of the National Institute of Health Sciences, and the animals were cared for in accordance with institutional guidelines as well as the Guidelines for Proper Conduct of Animal Experiments (Science Council of Japan, June 1st, 2006).

For histopathological and immunohistochemical examination, the excised urinary bladders were fixed in 10% neutral-buffered formalin for 24 hours, sliced along the longitudinal axis into strips of equal width and embedded in paraffin. Serial sections (4-μm thick) were prepared and stained with hematoxylin and eosin for histological observation and immunohistochemistry for DNA repair-associated proteins: γ-H2AX, MRE11 and XRCC1 (double-strand breaks); MGMT (direct damage reversal); MLH1 and MSH6 (mismatch repair); APE1 (base excision repair); DDB1 and ERCC1 (nucleotide excision repair); TREX1 (proofreading repair); SMC1 (cell cycle checkpoint); and RAD18 (post-replication repair). Table 1 provides details of the sources of the primary antibodies and conditions for the immunohistochemistry. Briefly, the serial sections were deparaffinized and hydrated through a graded series of ethanols and immersed in 3% H2O2/methanol solution for inhibition of endogenous peroxidase activity. For antigen retrieval, all sections were autoclaved in 10 mM citrate buffer (pH 6.0) for 15 minutes. After normal rabbit or goat serum treatment, the sections were incubated with primary antibodies for 12 hours at 4°C. Visualization of antibody binding was performed using a Histofine Simple Stain Rat MAX PO kit (Nichirei Corporation, Tokyo, Japan) and 3,3'-diaminobenzidine (DAB). All sections were counterstained with hematoxylin. The results of immunostaining in the epithelial cells, mesenchymal cells (smooth muscle cells and endothelium) and hyperplastic/neoplastic cells of the urinary bladder were classified into four degrees: – (almost negative), ± (scattered positive), + (occasionally positive) and ++.
Fig. 1. Immunohistochemistry of DNA repair enzymes for double-strand breaks, mismatch repair and base excision repair in urinary bladder tissue of F344 rats. Left column, untreated control; center column, BBN-induced PN hyperplasia; right column, BBN-induced carcinoma. Bars = 50 μm. (a–c) MRE11. (d–f) XRCC1. (g–i) MLH1. (j–l) MSH6. (m–o) APE1.
Fig. 2. Immunohistochemistry of DNA repair enzymes for nucleotide excision repair, proofreading repair, cell cycle checkpoint and post-replication repair in urinary bladder tissue of F344 rats. Left column, untreated control; center column, BBN-induced PN hyperplasia; right column, BBN-induced carcinoma. Bars = 50 μm. (a–c) DDB1. (d–f) ERCC1. (g–i) TREX1. (j–l) SMC1. (m–o) RAD18.
Histopathologically, the incidences of papillary-nodular (PN) hyperplasia and transitional cell carcinoma in the urinary bladder were 73.3% and 46.7%, respectively. The results of immunohistochemistry are summarized in Table 2. The nuclei of the BBN-stimulated normal-looking urothelium, PN hyperplasia and carcinoma showed positive staining for XRCC1 (Fig. 1d–f), MSH6 (Fig. 1j–l), APE1 (Fig. 1m–o), DDB1 (Fig. 2a–c), SMC1 (Fig. 2j–l) and RAD18 (Fig. 2m–o) similar to that of untreated control tissue. MRE11 (Fig. 1a–c), MLH1 (Fig. 1g–i), ERCC1 (Fig. 2d–f) and TREX1 (Fig. 2g–i) were expressed in the BBN-treated normal-appearing urothelium, PN hyperplasia and carcinoma more extensively than in the control group.

Most epithelial cells of the normal bladder in the control rats were negative for MGMT (Fig. 3a) and γ-H2AX (Fig. 4a). Contrary to the occasional positive staining in the BBN-stimulated normal urothelium and PN hyperplasia, carcinomas were entirely negative for MGMT (Fig. 3b–d). In the BBN-treated group, γ-H2AX-positive granules were observed not only in the nuclei of hyperplastic and neoplastic cells but also in the normal-appearing epithelium (Fig. 4b–d). It was noteworthy that some mitotic chromosomes of neoplastic cells were strongly positive for γ-H2AX (Fig. 4d). H2AX is a variant of the histone 2A family, which plays important roles not only in DNA packing but also in DNA repair. The rapid phosphorylation of H2AX at Serine 139, to become γ-H2AX, occurs in response to DNA double-strand breaks10. The phosphorylation of H2AX happens over a large region of chromatin surrounding double-strand breaks, leading to the accumulation of repair proteins11. The repair of double-strand breaks is extremely important to an individual, because this damage can lead to genome instability and cancer development12. Therefore, since its discovery in 199813, γ-H2AX has been used as a tool in multiple scientific fields, such as the in vitro assessment of preclinical drugs14–16. In addition, γ-H2AX has been applied to evaluation of DNA damage and genotoxicity screening for chemical agents17–19. In the present study, we demonstrated that γ-H2AX foci developed in the bladder epithelium of BBN-treated F344 rats using immunohistochemistry. The γ-H2AX-positive cells were observed not only in the proliferative lesions including PN hyperplasia and transitional cell carcinoma but also in the normal-like urothelium thirty-
Detection of γ-H2AX in the BBN-treated Rat Urinary Bladder

Three weeks after BBN treatment. The results indicate that BBN-induced DNA damage in bladder epithelial cells persists for a long period beyond the duration of administration. Our results also suggest the possibility that γ-H2AX is suitable for the early detection of in vivo genotoxicity in the urinary bladder and that the tissue-specific carcinogenicity of BBN is associated with double-strand breaks in the bladder epithelial cells.

MGMT is known as a major enzyme for direct damage reversal such as oxidation of guanine residues or alkylation of DNA bases. In this study, MGMT expression was occasionally observed in BBN-treated hyperplastic cells, while the non-treated urothelium was negative. Interestingly, the neoplastic cells were almost negative for MGMT, suggesting that MGMT acts only in the initial stage of bladder carcinogenesis. Yoshimi et al. previously reported that the DNA repair response to N-methyl-N′-nitro-N-nitrosoguanidine (MNNG) is reduced in the hyperplastic bladder epithelium of BBN-treated rats. These results indicate that suppression of DNA repair enzymes in specific stages of cancer development could have key roles in BBN-induced bladder carcinogenesis.

MRE11, MLH1, ERCC1 and TREX1 here showed increased expression in BBN-treated rats as compared with control rats. These enzymes may be associated with BBN-induced DNA damage and cancer development, at least to some extent. As shown in control rats, other DNA repair enzymes examined in this study (XRCC1, MSH6, APE1, DDB1, SMC1 and RAD18) are constitutively expressed in epithelial or mesenchymal cells of the urinary bladder. Since the expression pattern was similar in BBN-treated rats, these enzymes appear unlikely to be directly associated with BBN-induced bladder carcinogenesis.

In summary, the present study demonstrated that BBN treatment increased expression of several DNA repair enzymes and phosphorylation of histone H2AX in the urinary bladder. These results suggest that γ-H2AX could have potential as a useful biomarker in the early detection of genotoxicity in the rat urinary bladder. To the best of our knowledge, this is the first report demonstrating expression of γ-H2AX during bladder carcinogenesis. Although further investigations are needed, including comparison of results with non-genotoxic bladder carcinogens, our present study indicated potential application of γ-H2AX for rapid evaluation of tissue-specific genotoxicity.

Fig. 4. Immunohistochemical findings for γ-H2AX in urinary bladder tissue of F344 rats. Bars = 25 (a, b and c) or 50 (d) μm. (a) Untreated control. (b) BBN-stimulated bladder epithelium. (c) BBN-induced PN hyperplasia. (d) BBN-induced carcinoma. Note mitotic neoplastic cells (arrows) are positive.
Acknowledgments: We thank Ayako Saikawa and Yoshimi Komatsu for expert technical assistance in processing histological materials. This work was supported by a Grant-in-Aid from the Ministry of Health, Labour and Welfare, Japan.

References

1. Shi J, Krsmmanovic L, Bruce S, Kelly T, Paranjpe M, Szabo K, Arevalo M, Atta-Safoh S, Debelie F, LaForce MK, Sly J, and Springer S. Assessment of genotoxicity induced by 7,12-dimethylbenz(a)anthracene or diethylnitrosamine in the Pig-a, micronucleus and Comet assays integrated into 28-day repeat dose studies. Environ Mol Mutagen. 52: 711–720. 2011. [Medline] [CrossRef]

2. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 411: 366–374. 2001. [Medline] [CrossRef]

3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, and Forman D. Global cancer statistics. CA Cancer J Clin. 61: 69–90. 2011. [Medline] [CrossRef]

4. He Z, Kosinska W, Zhao ZL, Wu XR, and Guttenplan JB. Tissue-specific mutagenesis by N-butyl-N-(4-hydroxybutyl)nitrosamine as the basis for urothelial carcinogenesis. Mutat Res. 742: 92–95. 2012. [Medline] [CrossRef]

5. Wei M, Wanibuchi H, Morimura K, Salim EI, Moku M, Doi K, Mitsuhashi M, Masuda C, Shen J, Kinoshita A, and Fukushima S. Lack of preventive efficacy of FK228, a histone deacetylase inhibitor, against N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in p53+/− and p53+/+ mice. Anticancer Res. 24: 785–790. 2004. [Medline] [CrossRef]

6. Ishii N, Wei M, Kakehashi A, Doi K, Yamano S, Inaba M, and Wanibuchi H. Enhanced urinary bladder, liver and colon carcinogenesis in Zucker diabetic fatty rats in a multigorgan carcinogenesis bioassay: evidence for mechanisms involving activation of PIK3 signaling and impairment of p53 on urinary bladder carcinogenesis. J Toxicol Pathol. 24: 25–36. 2011. [Medline] [CrossRef]

7. Airoldi I, Magagnotti C, Bonfanti M, Chiappetta L, Lolli M, Medana C, De Gregorio G, and Fanelli R. Detection of O6-butyl- and O6-(4-hydroxybutyl)guanine in urothelial and hepatic DNA of rats given the bladder carcinogen N-nitrosobutyl(4-hydroxybutyl)amine. Carcinogenesis. 15: 2297–2301. 1994. [Medline] [CrossRef]

8. Ozawa A, Tanji N, Kikugawa T, Sasaki T, Yanagihara Y, Miura N, and Yokoyama M. Inhibition of bladder tumour growth by histone deacetylase inhibitor. BJU Int. 105: 1181–1186. 2010. [Medline] [CrossRef]

9. Tsuda H, Miyata Y, Hagiwara A, Hasegawa R, Shirai T, and Ito N. Damage and repair of DNA in urinary bladder epithelium of rats treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Gann. 68: 781–783. 1977. [Medline]

10. Pilch DR, Seldelnikova OA, Redon C, Celeste A, Nussenzweig A, and Bonner WM. Characteristics of γ-H2AX foci at DNA double-strand breaks sites. Biochem Cell Biol. 81: 123–129. 2003. [Medline] [CrossRef]

11. Rogakou EP, Boon C, Redon C, and Bonner WM. Mega-base chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol. 146: 905–916. 1999. [Medline] [CrossRef]

12. Celeste A, Difilippantonio S, Difilippantonio MJ, Fernandez-Capetillo O, Pilch DR, Seldelnikova OA, Eckhaus M, Ried T, Bonner WM, and Nussenzweig A. H2AX haploinsufficiency modifies genomic stability and tumor susceptibility. Cell. 114: 371–383. 2003. [Medline] [CrossRef]

13. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, and Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 273: 5858–5868. 1998. [Medline] [CrossRef]

14. Garcia-Canton C, Anand A, and Meredith C. γH2AX as a novel endpoint to detect DNA damage: Applications for the assessment of the in vitro genotoxicity of cigarette smoke. Toxicol In Vitro. 26: 1075–1086. 2012. [Medline] [CrossRef]

15. Watters GP, Smart DJ, Harvey JS, and Austin CA. H2AX phosphorylation as a genotoxicity endpoint. Mutat Res. 679: 50–58. 2009. [Medline] [CrossRef]

16. Kuo LJ, and Yang LX. γ-H2AX – a novel biomarker for DNA double-strand breaks. In Vivo. 22: 305–309. 2008. [Medline] [CrossRef]

17. Smart DJ, Ahmedi KP, Harvey JS, and Lynch AM. Genotoxicity screening via the γH2AX by flow assay. Mutat Res. 715: 25–31. 2011. [Medline] [CrossRef]

18. Smart DJ, Halicka HD, Schmuck F, Darzykiewicz Z, and Williams GM. Assessment of DNA double-strand breaks and γH2AX induced by the topoisomerase II poisons etoposide and mitoxantrone. Mutat Res. 641: 43–47. 2008. [Medline] [CrossRef]

19. Zhou C, Li Z, Diao H, Yu Y, Zhu W, Dai Y, Chen FF, and Yang J. DNA damage evaluated by γH2AX by flow assay. Mutat Res. 604: 8–18. 2006. [Medline] [CrossRef]

20. Christmann M, Verbeek B, Roos WP, and Kaina B. O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: Enzyme activity, promoter methylation and immunohistochemistry. Biochim Biophys Acta. 1816: 179–190. 2011. [Medline]

21. Yoshimi N, Shinoda T, Tanaka T, Mori Y, and Mori H. Reduced DNA repair response of carcinogen-induced hyperplastic cells in rat urinary bladder exposed to N-methyl-N’-nitro-N-nitrosoguanidine in organ culture. Res Comm Chem Pathol Pharmacol. 63: 93–100. 1989. [Medline]